###begin article-title 0
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wts </italic>
###xml 351 357 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 565 580 <span type="species:ncbi:10090">transgenic mice</span>
Lats1 (large tumor suppressor 1) codes for a serine/threonine kinase that plays a role in the progression through mitosis. Genetic studies demonstrated that the loss of LATS1 in mouse, and of its ortholog wts (warts) in Drosophila, is associated with increased cancer incidence. There are conflicting reports, however, as to whether overexpression of Lats1 inhibits cell proliferation. CUX1 is a transcription factor that exists in different isoforms as a result of proteolytic processing or alternative transcription initiation. Expression of p110 and p75 CUX1 in transgenic mice increases the susceptibility to cancer in various organs and tissues. In tissue culture, p110 CUX1 was shown to accelerate entry into S phase and stimulate cell proliferation.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 221 227 221 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 246 250 246 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 584 599 <span type="species:ncbi:10090">transgenic mice</span>
Genome-wide location arrays in cell lines of various cell types revealed that Lats1 was a transcriptional target of CUX1. Scanning ChIP analysis confirmed that CUX1 binds to the immediate promoter of Lats1. Expression of Lats1 was reduced in cux1-/- MEFs, whereas it was increased in cells stably or transiently expressing p110 or p75 CUX1. Reporter assays confirmed that the immediate promoter of Lats1 was sufficient to confer transcriptional activation by CUX1. Lats1 was found to be overexpressed in tumors from the mammary gland, uterus and spleen that arise in p110 or p75 CUX1 transgenic mice. In tissue culture, such elevated LATS1 expression did not hinder cell cycle progression in cells overexpressing p110 CUX1.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wts </italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 313 318 <span type="species:ncbi:9606">human</span>
While inactivation of Lats1/wts in mouse and Drosophila can increase cancer incidence, results from the present study demonstrate that Lats1 is a transcriptional target of CUX1 that can be overexpressed in tumors of various tissue-types. Interestingly, two other studies documented the overexpression of LATS1 in human cervical cancers and basal-like breast cancers. We conclude that, similarly to other genes involved in mitotic checkpoint, cancer can be associated with either loss-of-function or overexpression of Lats1.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wts</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wts</italic>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 630 636 630 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 716 720 716 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wts </italic>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 763 768 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 983 989 983 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 1160 1161 1160 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1162 1163 1162 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1190 1196 1190 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 1327 1328 1327 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1329 1331 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 79 85 <span type="species:ncbi:9606">humans</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 1055 1060 <span type="species:ncbi:9606">human</span>
###xml 1266 1271 <span type="species:ncbi:9606">human</span>
The large tumor suppressor (Lats)/Warts (wts) gene is conserved from insect to humans and codes for a serine/threonine kinase that was successively implicated as a tumor suppressor, a regulator of mitosis and a key component of the so-called Hippo pathway that controls the coordination between cell proliferation and apoptosis (reviewed in [1,2]). Mutations in the Drosophila lats1 homolog, warts (wts), were found originally to cause various developmental defects and dramatic overproliferation phenotypes including the development of tumors in various tissues [3,4]. Complementation assays in flies demonstrated that the human LATS1 gene was able to suppress tumour growth and rescue all developmental defects of wts mutants including embryonic lethality [5]. Lats1-deficient mice spontaneously developed non-metastatic ovarian stromal cell tumours and metastatic large soft tissue sarcomas with a penetrance of 100% and 14%, respectively [6]. Loss-of-heterozygosity (LOH) of the LATS1 chromosomal locus at 6q24-25.1 has been reported in a fraction of human breast cancers and salivary duct carcinomas, but inactivating point mutations have not been found [7,8]. Hypermethylation of the LATS1 gene promoter and reduction in mRNA expression was documented in some human breast cancers, soft tissue sarcomas and astrocytomas [9-11].
###end p 9
###begin p 10
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 703 704 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
No substrate of LATS1 was known until the hippo pathway was deciphered and a downstream transcriptional effector was identified. The Hippo (Hpo) pathway comprises two kinase/adaptor complexes and a transcription factor whose phosphorylation status controls its sub-cellular localization. In Drosophila, the Hippo/Salvador (Hpo/Sav) complex can phosphorylate and activate WARTS (Wts) [12]. In turn, the (Wts/Mats) complex phosphorylates Yorkie, thereby maintaining it into the cytoplasm [13,14]. Inactivating mutations in hpo, sav, mats and wtz or overexpression of yki produce similar phenotypes such as increased cell proliferation, and diminished apoptosis, as well as tissue overgrowth (reviewed in [1]). Mammals share a similar pathway whereby the Mst2/WW45 phosphorylates LATS1 [15], and the LATS1/Mob1 complex phosphorylates YAP1 to keep it in the cytoplasm [13,16].
###end p 10
###begin p 11
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1336 1338 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 642 647 <span type="species:ncbi:9606">human</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
###xml 1069 1074 <span type="species:ncbi:4932">yeast</span>
LATS1 was localized to centrosomes in interphase cells but associated with the mitotic apparatus during mitosis [17]. The fraction of LATS1 proteins present at the spindle pole bodies during mitosis was shown to be phosphorylated by cyclin B/Cdc2 [18]. LATS1 also associated with zyxin on the mitotic apparatus [19], and colocalized with, and inhibited the activity of, LIMK1 at the actomyosin contractile ring during cytokinesis [20]. These findings provided convincing evidence that LATS1 plays a role in mitosis, however, there are conflicting data as to whether Lats1 inhibits or stimulates progression through mitosis. Overexpression of human LATS1 in MEF cells and human tumor cell lines caused the inhibition of Cdc2 kinase activity and this was associated with cell cycle arrest in G2/M or apoptosis [5,21,22]. On the other hand, LATS1 was found to stimulate cytokinesis by negatively regulating LIMK1 and actin polymerization [20]. Moreover, LATS1 belongs to the nuclear Dbf2-related (NDR) family of protein kinases which are involved in cell cycle control in yeast [23]. Indeed, LATS1 forms with MOB1 a complex that localizes at the centrosomes and midbody, and overexpression of LATS1 allowed cells to overcome the spindle checkpoint, whereas siRNA against LATS1 or Mob1A extended telophase, but not other phases of mitosis [24]. These results led the authors to propose that LATS1 is a component of the mammalian mitotic exit network. In this model, the previously described ability of LATS1 to arrest cells in G2 could be explained if the excessively high expression of LATS1 caused the premature inactivation of Cdc2 and, as a consequence, prevented entry into mitosis.
###end p 11
###begin p 12
###xml 6 8 6 8 <underline xmlns:xlink="http://www.w3.org/1999/xlink">cu</underline>
###xml 17 20 17 20 <underline xmlns:xlink="http://www.w3.org/1999/xlink">x 1</underline>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1270 1272 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1390 1392 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 949 954 <span type="species:ncbi:9606">human</span>
CUX1 (cut homeobox 1) proteins are a family of transcription factors present in all metazoans and involved in the control of many cellular processes including determination of cell identity, cell cycle progression, cell-cell communication and cell motility (reviewed in [25,26]). At least three CUX1 protein isoforms have been described: p200, p110 and p75. The full-length protein, p200 CUX1, makes a rapid but unstable interaction with DNA and is responsible for the CCAAT-displacement activity that has been reported in early studies [27-29]. A shorter isoform, p110 CUX1, is generated as a result of proteolytic processing that does not takes place until the end of the G1 phase in normal cells but becomes constitutive in many transformed cells [30-32]. A third isoform, p75 CUX1, is generated from a shorter mRNA that is initiated within intron 20 and whose expression is restricted to certain cell-types and was found to be activated in some human breast tumors and cancer cell lines [33]. The p75 and p110 isoforms are much less abundant than the full-length isoform, however, in contrast to p200 both CUX1 short isoforms can make a stable interaction with DNA and, depending on promoter-context, can function as transcriptional repressor or activator [30,31,33-35]. Constitutive expression of p110 CUX1 was shown to stimulate cell proliferation by accelerating entry into S phase [36].
###end p 12
###begin p 13
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CUX1 </italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1337 1339 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 325 330 <span type="species:ncbi:9606">human</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 887 912 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 923 927 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1057 1061 <span type="species:ncbi:10090">mice</span>
###xml 1180 1195 <span type="species:ncbi:10090">transgenic mice</span>
Elevated CUX1 mRNA and protein expression was reported in primary tumors and cancer cell lines of various types [37-40]. A more detailed analysis revealed that expression of any one of the short isoforms was increased in some tumors and cancer cell lines. The steady-state level of p110 CUX1 was found to be elevated in many human uterine leiomyomas [40]. While proteolytic processing of CUX1 is tightly regulated during the cell cycle in normal cells, it is constitutive in many transformed cells as a result of increased expression of nuclear cathepsin L [30,32]. The intron 20-mRNA and p75 isoform was found to be aberrantly expressed in some primary breast tumors and cancer cell lines [33]. To investigate and compare the oncogenic potential of the 3 CUX1 isoforms, we used specific transgenesis to generate mice carrying a p75, p110 or p200 CUX1 transgene under the control of the mouse mammary tumor virus promoter (MMTV) and integrated into the hypoxanthine phosphoribosyltransferase (hprt) locus. In mixed genetic backgrounds, many virgin p75 CUX1 mice succumbed to myeloproliferative-disease (MPD)-like myeloid leukemias [41]. In the FVB genetic background, multiparous transgenic mice carrying a p75 or p110 CUX1 transgene developed malignancies in the mammary gland and other tissues, with a penetrance of approximately 50% [42]. Overall, these results demonstrated the oncogenic potential of p110 and p75 CUX1.
###end p 13
###begin p 14
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 524 529 524 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CIP1 </sup>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 761 767 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 838 844 838 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 998 1004 998 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1092 1098 1092 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1202 1217 <span type="species:ncbi:10090">transgenic mice</span>
To identify targets of CUX1 that are involved in cell cycle progression, we recently performed genome-wide location analysis using a promoter microarray and 8 cell lines of various cell-types [35]. Functional classes that were over-represented among targets included genes involved in mitosis and DNA replication initiation [35]. Expression of DNA replication targets was increased in cells over-expressing p110 CUX1, and was reduced following CUX1 knockdown. In contrast to the effect observed on most target genes, the p21CIP1 and cyclin H genes were repressed by p110 CUX1 [35,43]. The promoter-specific repression or activation of target promoters was confirmed in reporter assays [35]. One putative target that was identified in all location arrays is the Lats1 gene. In the present study, we performed experiments to verify whether Lats1 is a direct target of CUX1 and we investigated the regulatory effect of CUX1 on Lats1. We found that p110 and p75 CUX1 can stimulate the transcription of Lats1 both in reporter assays and in cell lines stably expressing p110 or p75 CUX1. Moreover, Lats1 expression was consistently elevated in tumors of various tissue-types that develop in p110 or p75 CUX1 transgenic mice.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
Lats1 Is Identified As a Putative Target of CUX1 in Cells of Various Tissue Types
###end title 16
###begin p 17
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 617 623 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 823 829 823 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1120 1126 1120 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1186 1188 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1702 1704 1702 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1742 1744 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1795 1801 1795 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1941 1947 1941 1947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
Genome location analysis using a promoter array was previously performed in triplicate using chromatin from 8 human cell lines of various cell types: breast tumor (Hs578T), cervical carcinoma (HeLa), kidney epithelial (HEK293), myeloid leukemia (K562, HEL), and B cell lymphoma (Ramos, U266, RPMI8266) ([35] and supplemental data therein). We utilized a genomic DNA microarray containing the region spanning 800 bp upstream and 200 bp downstream of transcription start sites of 18,660 human genes [44]. Strikingly, the Lats1 gene was identified as a putative target in all cell lines tested. The p values of the CUX1/Lats1 interaction observed in each cell line are shown in Table 1. To confirm that CUX1 binds to the promoter of the Lats1 gene, scanning ChIP was performed using primer pairs from different regions of the Lats1 locus and chromatin from Hs578T cells immunoprecipitated with CUX1 antibodies. Our results showed that CUX1 bound to the region immediately upstream of the transcription start site and amplified by primer pairs A and B (Fig. 1B, lanes 3 and 5). Note that this region was included within the Lats1 promoter sequences present on the promoter microarray (Fig. 1A, see thick line under the map). A weaker interaction was also observed within the first intron (Fig. 1B, lane 8). In contrast, no binding was observed to distal sequences located further downstream of the transcription start site (Fig. 1B, lanes 10 and 12). Interestingly, sequences matching the ATCRAT consensus binding site for the Cut repeat 3 and Cut homeodomain composite DNA binding domain of CUX1 were found at 2 positions upstream of the transcription start site and at one position within intron 1 (Fig. 1A, see black triangles below the map) [45]. Using the primer pair A, binding of CUX1 to the Lats1 immediate promoter was validated in all cell lines (data not shown). Altogether, these results demonstrate that CUX1 binds to the immediate Lats1 promoter in cells of various tissue types.
###end p 17
###begin p 18
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Scanning ChIP analysis of the <italic>LATS1 </italic>locus using CUX1 antibodies</bold>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 739 745 739 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
Scanning ChIP analysis of the LATS1 locus using CUX1 antibodies. (A) Diagram of the LATS1 locus. Exons are numbered and the transcription start site is indicated by an arrow. The positions of primer pairs used in the analysis of chipped DNA are indicated by arrows above the map. Primer sequences are given in Materials & Methods. The positions of p110 and p75 CUX1 consensus binding sites (ATCRAT) are indicated by black triangles below the map. The thick line shows the genomic sequences present on the promoter microarray that was used in the location array analysis. (B) Chromatin from Hs578T cells was immunoprecipitated with the CUX1-861 antibody and analyzed by PCR amplification using primers specific for different regions of the LATS1 locus. Templates for the PCR reactions were 0.1% total input DNA (T) or ChIP-purified DNA (IP).
###end p 18
###begin p 19
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
Lats1 is identified as a putative target of p110 CUX1 in 8 cell lines
###end p 19
###begin p 20
###xml 797 803 797 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 621 626 <span type="species:ncbi:9606">human</span>
###xml 758 763 <span type="species:ncbi:9606">human</span>
Genome-wide location analysis was performed using a panel of 8 human cell lines of various cell types: breast tumor (Hs578T), cervical carcinoma (HeLa), kidney epithelial (HEK293), myeloid leukemia (K562, HEL), and B cell lymphoma (Ramos, U266, RPMI8266). For each cell line, hybridization experiments were done in triplicate using three independent ChAP-enriched and input DNA samples (8 cell lines x 3 hybridizations = 24). ChAP-enriched DNA regions associated with p110 CUX1 were purified and labeled with Cy5 dye. Equal amounts of Cy5-labeled ChAP products and Cy3-labeled input DNA samples were co-hybridized onto a human genomic DNA microarray containing the region spanning 800 bp upstream and 200 bp downstream of transcription start sites of 18,660 human genes. P values observed for the Lats1 promoter are shown. The data is taken from [35].
###end p 20
###begin title 21
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
The immediate promoter region of LATS1 is sufficient for the regulation by CUX1
###end title 21
###begin p 22
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 905 911 905 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
We wanted to confirm whether the 1-Kbp LATS1 genomic region present on the promoter microarray was sufficient for transcriptional regulation by CUX1. The LATS1 promoter sequences were introduced into a luciferase reporter plasmid and luciferase activity was measured in the presence of effector plasmids expressing either p200, p110 or p75 CUX1. Previous studies have revealed that the full-length CUX1 isoform, p200, functions as a transcriptional repressor whereas the shorter CUX1 isoform, p110 and p75, can function as repressors or activators depending on promoter-context [30,34,35,43,46]. Expression was not significantly affected by p200 CUX1, but was stimulated in the presence of either p110 or p75 CUX1 (Fig. 2B, left panel). Moreover, the fold-activation by p110 CUX1 was proportional to the amount of effector plasmid (Fig. 2B, right panel). We conclude that the immediate promoter region of LATS1 is sufficient for its regulation by p110 and p75 CUX1.
###end p 22
###begin p 23
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CDP/Cux p110 and p75 isoforms increases <italic>Lats1 </italic>transcription activity in reporter assays</bold>
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 729 735 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
CDP/Cux p110 and p75 isoforms increases Lats1 transcription activity in reporter assays. (A) Diagram of the LATS1 reporter construct. The promoter region of the LATS1 gene, from nt -1463 to +310, was cloned into a luciferase reporter plasmid. (B) Hs578T cells were transfected with the LATS1 reporter plasmid together with vectors expressing either p200, p110 or p75 CUX1 or with an empty vector. 24 hours after transfection, whole cell extracts were prepared and processed to measure luciferase activity. The results are expressed as relative light units (RLU), normalized to beta-galactosidase activity from an internal control and the standard deviation of 3 transfections is shown. (C) NIH3T3 cells were transfected with the LATS1 reporter plasmid together with increasing amount of a vector expressing p110 CUX1 or with an empty vector. Samples were processed as detailed in (B).
###end p 23
###begin title 24
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
p110 and p75 CUX1 activate transcription of the endogenous Lats1 gene
###end title 24
###begin p 25
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 161 165 161 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 338 342 338 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 445 449 445 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 690 694 690 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 866 872 866 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 884 890 884 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1063 1069 1063 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 1314 1320 1314 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
###xml 174 179 <span type="species:ncbi:10090">mouse</span>
###xml 1108 1113 <span type="species:ncbi:9606">human</span>
We then verified the effect of CUX1 on the endogenous Lats1 gene. First, we compared Lats1 mRNA expression in mouse embryo fibroblasts (MEFs) derived from a cux1-/- knockout mouse or a wild type littermate [36]. RT-PCR analysis using two dilutions of the mRNA preparations showed that Lats1 expression was higher in wild type than in cux1-/- MEFs (Fig. 3A). This result suggested that CUX1 is required for optimal expression of Lats1. Next, cux1-/- MEFs were infected with a retroviral vector expressing p110 CUX1 or with a control empty vector and we measured Lats1 mRNA expression by quantitative real-time PCR amplification. Lats1 mRNA expression was increased on average 15-fold in cux1-/- MEF cells expressing p110 CUX1 (Fig. 3B). We then turned to cell lines that express CUX1 and asked whether increasing the level of p110 or p75 CUX1 would affect endogenous Lats1 expression. Lats1 mRNA steady-state level was increased approximately 3-fold in Hs578T breast tumor cells that were infected with the p110 CUX1 retroviral vector (Fig. 3B and 3C). Similarly, Lats1 expression was increased in the MCF10A human mammary epithelial cell line following infection with a retroviral vector expressing p75 (Fig. 3D). Altogether, these results demonstrate that p110 and p75 CUX1 stimulate expression of the endogenous Lats1 gene.
###end p 25
###begin p 26
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Endogenous <italic>Lats1 </italic>expression is regulated by CUX1</bold>
###xml 198 204 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 384 388 384 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 396 400 396 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 482 486 482 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 335 340 <span type="species:ncbi:10090">Mouse</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 501 506 <span type="species:ncbi:9606">human</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
###xml 768 773 <span type="species:ncbi:10090">mouse</span>
Endogenous Lats1 expression is regulated by CUX1. RNA was prepared from mouse embryo fibroblasts and various cell lines expressing either p110 or p75 CUX1 or carrying an empty vector, as indicated. Lats1 mRNA expression was analyzed by RT-PCR using GAPDH as a control. Amplicons were resolved by agarose gel electrophoresis (A-D). (A) Mouse embryo fibroblasts (MEFs) derived from cux1-/- and cux1+/+ mice. (B) Lats1 mRNA expression was measured by quantitative real-time PCR in cux1-/- MEF and Hs578T human breast tumor cells expressing p110 CUX1 or carrying an empty vector. GAPDH levels were used to normalize the samples. The values are the mean of three measurements and error bars represent standard deviation. (C) MCF10A human mammary epithelial cells (D) NMuMG mouse mammary epithelial cells.
###end p 26
###begin title 27
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Lats1 is over-expressed in tumors from CUX1 transgenic mice
###end title 27
###begin p 28
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4F</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 144 149 <span type="species:ncbi:10090">Mouse</span>
###xml 171 175 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 531 546 <span type="species:ncbi:10090">transgenic mice</span>
###xml 558 562 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 570 574 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 1149 1164 <span type="species:ncbi:10090">transgenic mice</span>
Transgenic mice have been engineered to express p75 or p110 CUX1 under the control of regulatory sequences from the long terminal repeat of the Mouse Mammary Tumor Virus (MMTV-LTR) [41]. To be able to compare the two CUX1 isoforms, specific transgenesis was used to integrate the transgene into the hypoxanthine phosphoribosyltransferase (hprt) locus [47]. In mixed genetic backgrounds, many virgin p75 CUX1 mice succumbed to myeloproliferative-disease (MPD)-like myeloid leukemias [41]. In the FVB genetic background, multiparous transgenic mice carrying a MMTV-p75 or MMTV-p110 CUX1 transgene developed malignancies primarily in the mammary gland [42]. In addition to mammary tumors, a small number of tumors were also detected in other tissues. In particular, a number of sarcomas with features resembling that of histiocytic sarcomas were observed in the uterus and liver of several mice. An example of this type of tumor is presented (Fig. 4). The uterus was grossly enlarged (Fig. 4B), and a large number of histiocytic/dendritic cells were observed in sections taken from the uterus and the liver (Fig. 4D and 4F). Overall, results from CUX1 transgenic mice indicate that overexpression of p110 or p75 CUX1 can increases the incidence of cancer in various cell types.
###end p 28
###begin p 29
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p110 CUX1 transgenic mice develop uterine histiocytic sarcomas with liver infiltration</bold>
###xml 10 25 <span type="species:ncbi:10090">transgenic mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 258 273 <span type="species:ncbi:10090">transgenic mice</span>
p110 CUX1 transgenic mice develop uterine histiocytic sarcomas with liver infiltration. (A, B) Pictures of the uterus from wild-type (A) and p110 CUX1 transgenic (B) mice. (C-F) H&E staining of the uterus (C, D) and liver (E, F) from wild-type and p110 CUX1 transgenic mice respectively.
###end p 29
###begin p 30
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 465 470 465 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 443 458 <span type="species:ncbi:10090">transgenic mice</span>
We analyzed Lats1 mRNA expression in 4 mammary gland tumors, 2 uterine tumors and 3 spleens from mice suffering from MLPD-like myeloid leukemias. In the case of mammary tumors, RNA from an adjacent normal mammary gland served as a control. In the case of uterine tumors and diseased spleens, we used RNA from the corresponding normal tissue of a non transgenic littermate. In all cases, Lats1 mRNA expression was increased in tumors from CUX1 transgenic mice (Fig. 5A, B and 5C).
###end p 30
###begin p 31
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Lats1 </italic>is overexpressed in tumors from p75 and p110 CUX1 transgenic mice</bold>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 56 71 <span type="species:ncbi:10090">transgenic mice</span>
###xml 490 505 <span type="species:ncbi:10090">transgenic mice</span>
Lats1 is overexpressed in tumors from p75 and p110 CUX1 transgenic mice. RNA was prepared from tumors and either adjacent normal tissue (mammary gland) or equivalent normal tissue from a non-transgenic littermate. Lats1 mRNA expression was analyzed by RT-PCR using GAPDH or beta-actin as a control, as indicated. (A) Mammary gland tumors and adjacent normal mammary gland. (B) Uterine tumors and normal uterus from a non-transgenic littermate. (C) Enlarged and normal spleens from p75 CUX1 transgenic mice and non-transgenic littermates, respectively.
###end p 31
###begin title 32
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
Overexpression of Lats1 in NMuMG mammary epithelial cells does not hinder cell cycle progression
###end title 32
###begin p 33
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 152 158 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 578 584 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 1136 1141 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 1268 1270 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 1338 1344 1338 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 466 471 <span type="species:ncbi:10090">mouse</span>
Loss of Lats1 and its ortholog warts has been associated with increased susceptibility to various types of cancers [2,3,6]. This protective function of Lats1 against cancer has been linked to its role in cell cycle progression during mitosis. However, it is not clear from previous studies whether overexpression of Lats1 would necessarily cause a delay in cell cycle progression [21,24]. We therefore investigated cell cycle progression using non-transformed NMuMG mouse mammary epithelial cells carrying a p110 CUX1 retroviral vector or the empty vector. As shown in Fig. 6A, Lats1 expression was significantly higher in cells carrying the p110 CUX1 retrovirus. Cells were synchronized at the G1/S transition using the double thymidine block procedure and then allowed to proceed through the cell cycle. Samples taken at different times were stained with propidium iodide and the cell cycle profile of cells was analyzed by FACS analysis. This experiment was performed independently three times and representative results are presented (Fig. 6B). No delay in cell cycle progression was observed in cells over-expressing p110 CUX1 and Lats1. In fact, cells of the p110 CUX1 population reached the next G1 phase a little bit faster than the control vector-cells (Fig. 6B, see the 6-hour time point). We conclude that higher expression of Lats1 does not slow down progression through the S, G2 and mitosis phases of the cell cycle.
###end p 33
###begin p 34
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of <italic>Lats1 </italic>in NMuMG epithelial cells does not hinder cell cycle progression</bold>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 122 127 <span type="species:ncbi:10090">mouse</span>
Overexpression of Lats1 in NMuMG epithelial cells does not hinder cell cycle progression. (A) RNA was prepared from NMuMG mouse epithelial cells expressing p110 CUX1 or carrying an empty vector. Lats1 mRNA expression was analyzed by RT-PCR using GAPDH as a control. (B) Cells were synchronized at the G1/S transition using the double thymidine block procedure, and then released from the block and allowed to progress in the cell cycle. Nuclei were stained with propidium iodide and DNA content was determined by fluorescence-activated cell sorting (FACS) analysis. Cell cycle profiles were analyzed using the Watson model and the FlowJotrade mark software. The numbers below the FACS profiles indicate the percentage of cells with 2N DNA content (G0/G1 cells), between 2N and 4N DNA content (S phase cells) and 4N DNA content (G2/M cells).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 722 728 722 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 787 793 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 825 829 825 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 837 841 837 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 882 888 882 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 918 924 918 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1008 1012 1008 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1090 1096 1090 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1212 1217 1212 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B, C</xref>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 1385 1391 1385 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1585 1587 1585 1587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1591 1593 1591 1593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1774 1776 1774 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1777 1779 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1780 1782 1780 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1915 1917 1915 1917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 2067 2069 2067 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
We have presented evidence demonstrating that the Lats1 gene is a transcriptional target of the CUX1 homeodomain protein. The Lats1 gene promoter region was identified in 8 of 8 genome-wide location arrays using CUX1-associated chromatin from cell lines of various tissue types (Table 1). Scanning ChIP analysis confirmed that CUX1 binds to genomic sequences located immediately upstream of the Lats1 transcription start site and, to a lesser extent, to sequences within the first intron (Fig. 1). The 5' flanking sequences were found to include two CUX1 consensus binding sites, and the intron 1 sequences included one such binding site (Fig. 1). A luciferase reporter plasmid containing the immediate promoter region of Lats1 was activated by p110 and p75 CUX1 (Fig. 2). Comparison of Lats1 steady state mRNA levels in cux1-/- and cux1+/+ MEFs indicated that CUX1 is required for Lats1 expression (Fig. 3A). Indeed, Lats1 expression was stimulated up to 15-fold upon the reintroduction of p110 CUX1 in cux1-/- MEFs (Fig. 3B). Interestingly, in cell lines that are not defective for CUX1, Lats1 expression was also stimulated following the infection of cells with a retrovirus expressing p110 or p75 CUX1 (Fig. 3B, C and 3D and 6A). As CUX1 was shown to participate in the transcriptional activation of several genes that play a role in DNA replication and mitosis, the regulation of Lats1 by CUX1 is consistent with the function of CUX1 in cell cycle progression [35]. CUX1 DNA binding and transcriptional activities were previously shown to be activated at the end of the G1 phase [30,31,43]. Once activated, CUX1 cooperates with other factors to activate the transcription of genes that are required for the replication of DNA and later the completion of cell division [34-36,46]. Constitutive expression of p110 CUX1 was indeed shown to accelerate entry into S phase without apparent deleterious consequences [36]. Cells continued to progress unabated through the cell cycle and proliferated faster and reached a higher density at saturation than control cells [36].
###end p 36
###begin p 37
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 925 931 925 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1119 1121 1119 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1230 1236 1230 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 1414 1416 1414 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1417 1419 1417 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 501 516 <span type="species:ncbi:10090">transgenic mice</span>
Transgenic mice expressing p75 or p110 CUX1 developed tumors in various tissues including the hematopoietic system, the mammary gland and the uterus. In mammary tumors, in MLPD-like leukemias and in uterine tumors, Lats1 mRNA expression was consistently elevated in tumors as compared to control normal tissues (Fig. 5). Although this finding is consistent with the fact that CUX1 activates Lats1 transcription, there is an apparent discrepancy between the elevated expression of Lats1 in tumors from transgenic mice and the purported role of LATS1 as a tumor suppressor. Obviously, tumors can grow in spite of elevated LATS1 expression. Moreover, when cell cycle progression was monitored in tissue culture, we did not observe any delay in cells that over-expressed both p110 CUX1 and Lats1 (Fig. 6). In this respect, our results are in agreement with a previous study showing that a moderate increase (from 2 to 5-fold) in Lats1 expression did not hinder cell cycle progression [24]. In contrast, the introduction of a Lats1 gene into cells by Adenovirus-mediated gene transfer caused a block at the G2/M transition [21]. We favor the interpretation proposed by Bothos et al. suggesting that the extremely high concentration of Lats1 that was achieved with an Adenovirus vector may have caused the premature inhibition of cyclin B/Cdk1 at the end of the G2 phase, instead of during telophase as in normal cells [21,24].
###end p 37
###begin p 38
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 848 854 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 981 987 981 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 169 174 <span type="species:ncbi:10090">mouse</span>
###xml 501 506 <span type="species:ncbi:9606">human</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
There is solid genetic evidence in Drosophila and mice to establish the role of LATS1 as a tumor suppressor. Loss-of-function of warts in Drosophila and of Lats1 in the mouse has been shown to increase the susceptibility to cancers in various tissues [3,4,6]. Yet, the role of LATS1 as a tumor suppressor does not necessarily mean that elevated expression of LATS1 would hinder cell proliferation and prevent tumor growth, as demonstrated here and in another study [24]. Moreover, genetic analysis in human tumors did not provide a compelling case for the inactivation of LATS1 in human cancers. While hypermethylation of the LATS1 promoter has been reported [9-11], these cases are not common and so far no inactivating mutation has been documented. Interestingly, a search of the Oncomine database revealed only two studies where a difference in LATS1 expression was observed between normal and cancer samples [48]. In both cases, cervical cancers and basal-like breast cancers, LATS1 expression was higher in the tumor than in the normal tissue [49,50].
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
In summary, while loss-of-function of Lats1 can predispose to cancer, there is compelling evidence both from transgenic mouse models and from human cancers that Lats1 can be overexpressed in tumors. Lats1 is not unique in this respect. Indeed, many genes that play a role in the mitotic checkpoint were found to be either over-expressed or inactivated in various cancers [51,52]. While the mechanistic details remain to be deciphered, the overall picture that has emerged suggests that the mitotic regulatory network can be perturbed through both the elevated or decreased expression of some of its components (reviewed in [52]).
###end p 40
###begin title 41
Methods
###end title 41
###begin title 42
Cell Culture
###end title 42
###begin p 43
###xml 168 174 <span type="species:ncbi:9913">bovine</span>
NIH3T3, Hs578T and NMuMG cells were cultured in Dulbecco's Modified Minimum Essential Medium (DMEM) supplemented with penicillin-streptomycin, glutamine, and 10% fetal bovine serum (FBS) (Gibco); 10 mug/ml insulin was added to the medium for NMuMG cells.
###end p 43
###begin title 44
Cell synchronization and Fluorescence -activated cell sorting (FACS) analysis
###end title 44
###begin p 45
###xml 187 189 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 634 636 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
NMuMG cells (100,000 cell/plate) were cultured in DMEM medium supplemented with 10% FBS and 10 mug/ml insulin. Synchronization in G1/S was performed using the double thymidine procedure [53]. Cells were cultured overnight in DMEM plus 10% FBS supplemented with 2 mM thymidine, washed the next day, cultured for 10 hours in DMEM plus 10% FBS and finally further incubated overnight in the presence of 2 mM thymidine (Thymidine 0 h). To allow cells to progress in the cell cycle, the medium was replaced with DMEM plus 10% FBS and cells were harvested at different times thereafter. FACS analysis was performed as previously described [43].
###end p 45
###begin title 46
Chromatin Immunoprecipitation
###end title 46
###begin p 47
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
We used 4 x 108 Hs578T cells for the chromatin immunoprecipitation with anti CUX1 antibodies 861 and 1300, using our previously described protocol [34,35]. Chromatin affinity purification (ChAP) was performed for the genome-wide location analysis. A complete protocol for ChAP as well as an excel file detailing the results in 8 cell lines are provided in the supplemental data of Harada et al., 2008 [35]. For scanning ChiP, the following primers were used: primer that amplify region A, 5'-TTGGGTTTGATGTATAAGGTACGG-3' and 5'-GTGCTGGGATTACAGGCGTGAGAC-3'; region B, 5'-TCTTATCTGTCAACCGCATCCGTAGA-3' and 5'-GGACCGTACCTTATACATCAAACCCAACGA-3'; region C, 5'-AAAGTGTTAATTTGGGTTGAA-3' and 5'-CATGAAGATACAGCGTTGCTT-3'; region D, 5'-AAAGTGTTAATTTGGGTTGAA-3' and 5'-CATGAAGATACAGCGTTGCTT-3'; region E, 5'-CAGGCTGGAATTGGG TATCTTATT-3'and 5'-ATG GGAAACTGGAGGTGGGCTAAC-3'
###end p 47
###begin title 48
Luciferase construct and luciferase assay
###end title 48
###begin p 49
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1</italic>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
LATS1 5' flanking sequences were amplified from Hs578T genomic DNA using the following primers 5'-ATCATTCCACCTCTGCTTTCCCTGC-3' and 5'-TGGGGCAGAGCGGGGAGACG-3' which amplifies a 1775 base pair fragment that include 1464 base pair upstream of the transcription start site, start site and 311 base pairs of exon 1. The PCR product was cloned into XhoI and HindIII site of pGL3 (Promega). NIH3T3 cells and Hs578T cells were transiently transfected with CUX1 p200, p110 (831-1505) or p75 (1062-1505) and pGL3-Lats1. We utilized 2 different vectors for the CUX1 constructs pTriEx1.1 (Novagen) and pXJ42 [54], both revealing similar results. Luciferase assay was performed as previously described [30].
###end p 49
###begin title 50
RNA extraction, reverse transcriptase PCR (RT-PCR) and real-time PCR
###end title 50
###begin p 51
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lats1 </italic>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LATS1 </italic>
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
###xml 546 551 <span type="species:ncbi:9606">Human</span>
RNA was extracted using TRIzol reagent (Invitrogen) followed by cDNA preparation using the superscript II RNase H-reverse transcriptase kit (Invitrogen) as provided in the manufacturer manual. Real-time PCR was performed on a LightCycler instrument (Roche) using the FastStart DNA Master SYBR Green kit (Roche). The following oligonucleotides were used for the amplification of mouse Lats1 cDNA: 5'-TAGAATGGGCATCTTTCCTGA-3' and 5'-TGCTATCTTGCCGTGGGT-3' (Fig. 3A and 3D), and 5'-AATAGGAGCGTTTGGTGAAGTC-3' and 5'-TGTGTCCATCTGAAGCCAGTG-3' (Fig. 5). Human LATS1 cDNA: 5'-ACCGCTTCAAATGTGACTGTGATGCCACCT-3' and 5'-CTTCCTTGGGCAAGCTTGGCTGATCCTCT-3'.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The authors declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
###xml 194 209 <span type="species:ncbi:10090">transgenic mice</span>
RS carried out scanning ChIP, luciferase assays, RT-PCR assays and drafted the manuscript. RH carried out the ChIP-chip assays and the cell cycle progression studies. CC analyzed tumors in CUX1 transgenic mice. RB carried RT-PCR assays. CV performed statistical analysis of ChIP-chip data. AN conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
This research was supported by grant #019389 from the Canadian Cancer Society to A.N.
###end p 57
###begin article-title 58
The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals
###end article-title 58
###begin article-title 59
The role of lats in cell cycle regulation and tumorigenesis
###end article-title 59
###begin article-title 60
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase
###end article-title 60
###begin article-title 61
###xml 64 69 <span type="species:ncbi:9606">human</span>
The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation
###end article-title 61
###begin article-title 62
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 23 46 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity
###end article-title 62
###begin article-title 63
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction
###end article-title 63
###begin article-title 64
###xml 48 53 <span type="species:ncbi:9606">human</span>
Molecular analysis of the h-warts/LATS1 gene in human breast cancer
###end article-title 64
###begin article-title 65
Chromosome 6 deletion and candidate tumor suppressor genes in adenoid cystic carcinoma
###end article-title 65
###begin article-title 66
###xml 73 78 <span type="species:ncbi:9606">human</span>
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma
###end article-title 66
###begin article-title 67
###xml 142 147 <span type="species:ncbi:9606">human</span>
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers
###end article-title 67
###begin article-title 68
###xml 59 64 <span type="species:ncbi:9606">human</span>
Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma
###end article-title 68
###begin article-title 69
hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts
###end article-title 69
###begin article-title 70
Elucidation of a universal size-control mechanism in Drosophila and mammals
###end article-title 70
###begin article-title 71
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP
###end article-title 71
###begin article-title 72
###xml 41 46 <span type="species:ncbi:9606">human</span>
The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1
###end article-title 72
###begin article-title 73
Tumor suppressor LATS1 is a negative regulator of oncogene YAP
###end article-title 73
###begin article-title 74
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human homolog of Drosophila warts tumor suppressor, h-warts, localized to mitotic apparatus and specifically phosphorylated during mitosis
###end article-title 74
###begin article-title 75
WARTS tumor suppressor is phosphorylated by Cdc2/cyclin B at spindle poles during mitosis
###end article-title 75
###begin article-title 76
Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor
###end article-title 76
###begin article-title 77
LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis
###end article-title 78
###begin article-title 79
LATS1 tumor suppressor regulates G2/M transition and apoptosis
###end article-title 79
###begin article-title 80
NDR family of AGC kinases - essential regulators of the cell cycle and morphogenesis
###end article-title 80
###begin article-title 81
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human LATS1 is a mitotic exit network kinase
###end article-title 81
###begin article-title 82
Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development
###end article-title 82
###begin article-title 83
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
The multiple roles of CUX1: Insights from mouse models and cell-based assays
###end article-title 83
###begin article-title 84
CCAAT displacement activity involves Cut repeats 1 and 2, not the Cut homeodomain
###end article-title 84
###begin article-title 85
Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut
###end article-title 86
###begin article-title 87
S Phase-Specific Proteolytic Cleavage Is Required to Activate Stable DNA Binding by the CDP/Cut Homeodomain Protein
###end article-title 87
###begin article-title 88
A Cathepsin L Isoform that Is Devoid of a Signal Peptide Localizes to the Nucleus in S Phase and Processes the CDP/Cux Transcription Factor
###end article-title 88
###begin article-title 89
Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation
###end article-title 89
###begin article-title 90
Characterization of a tissue-specific CDP/Cux isoform, p75, activated in breast tumor cells
###end article-title 90
###begin article-title 91
CDP/Cux stimulates transcription from the DNA polymerase alpha gene promoter
###end article-title 91
###begin article-title 92
Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes
###end article-title 92
###begin article-title 93
The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase
###end article-title 93
###begin article-title 94
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays
###end article-title 94
###begin article-title 95
Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements
###end article-title 95
###begin article-title 96
CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness
###end article-title 96
###begin article-title 97
###xml 73 78 <span type="species:ncbi:9606">human</span>
Expression of N-terminally truncated isoforms of CDP/CUX is increased in human uterine leiomyomas
###end article-title 97
###begin article-title 98
###xml 11 15 <span type="species:ncbi:10090">Mice</span>
Transgenic Mice Expressing the p75 CCAAT-Displacement Protein/Cut Homeobox Isoform Develop a Myeloproliferative Disease-Like Myeloid Leukemia
###end article-title 98
###begin article-title 99
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 34 38 <span type="species:ncbi:10090">Mice</span>
MMTV-p75 and p110 CUX1 Transgenic Mice Develop Mammary Tumors of Various Histological Types
###end article-title 99
###begin article-title 100
The mammalian Cut homeodomain protein functions as a cell-cycle dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase
###end article-title 100
###begin article-title 101
From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response
###end article-title 101
###begin article-title 102
###xml 52 57 <span type="species:ncbi:9606">human</span>
DNA-binding specificity of the cut repeats from the human cut-like protein
###end article-title 102
###begin article-title 103
The p110 isoform of CUX1 Cooperates with E2F Transcription Factors in the Transcriptional Activation of Cell Cycle-Regulated Gene Promoters
###end article-title 103
###begin article-title 104
###xml 12 27 <span type="species:ncbi:10090">transgenic mice</span>
Single-copy transgenic mice with chosen-site integration [see comments]
###end article-title 104
###begin article-title 105
ONCOMINE: a cancer microarray database and integrated data-mining platform
###end article-title 105
###begin article-title 106
###xml 42 47 <span type="species:ncbi:9606">human</span>
X chromosomal abnormalities in basal-like human breast cancer
###end article-title 106
###begin article-title 107
###xml 54 74 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 88 108 <span type="species:ncbi:10566">human papillomavirus</span>
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers
###end article-title 107
###begin article-title 108
Does aneuploidy cause cancer?
###end article-title 108
###begin article-title 109
Aneuploidy acts both oncogenically and as a tumor suppressor
###end article-title 109
###begin article-title 110
The synthesis of acidic chromosomal proteins during the cell cycle of HeLa S-3 cells. I. The accelerated accumulation of acidic residual nuclear protein before the initiation of DNA replication
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells
###end article-title 111

